This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Ocular Drug Therapies / Oral Delivery of Macromolecules
October 26-27, 2022 | 2-Day Digital Conference
Digital Conference8:00AM EST // 1:00PM BST // 2:00PM CEST
Menu
Day 1 - Ocular Drug Therapies - October 26thkeyboard_arrow_right

Day 1 - Ocular Drug Therapies - October 26th - EST/EDT (Eastern Daylight, GMT-4)

keyboard_arrow_leftSearch & Filter
search
Day 1 - Ocular Drug Therapies - October 26th - EST/EDT (Eastern Daylight, GMT-4)
search
Showing 1 of 1 Streams
Day 1 - Ocular Drug Therapies - October 26th 08:00 - 08:05
Welcoming Remarks
  • Lottie Leinfellner - Digital Events Conference Producer, Informa Connect, UK
Day 1 - Ocular Drug Therapies - October 26th 08:05 - 08:35
Overviewing Current Approaches for Delivery of Therapeutics to the Eye
  • Sanjay Jain - Drug Delivery Systems Principal Engineer, Janssen, USA
Day 1 - Ocular Drug Therapies - October 26th 08:35 - 09:05
Panel Discussion: What is the Optimal Dosing Window for Ocular Therapies?
  • Michael O'Rourke - CEO, RE-Vana Therapeutics, UK
  • Michael W. Stewart - Ophthalmologist & Chair, Ophthalmology, Mayo Clinic, USA
Day 1 - Ocular Drug Therapies - October 26th 09:05 - 09:35
Coffee Break & Networking
Day 1 - Ocular Drug Therapies - October 26th 09:35 - 10:05
Sustained Release of Anti-VEGF TKI using Bio-erodible Implant for the Treatment of Wet Age-Related Macular Degeneration and Other Retina Conditions
  • Jay Duker - Chief Operating Officer, EyePoint Pharmaceuticals, USA
Day 1 - Ocular Drug Therapies - October 26th 10:05 - 10:35
Long-Acting Implants for Delivery of Biologics to the Eye
  • Raj Thakur - Professor in Pharmaceutics & Founder/CTO, Queen's University Belfast & Re-Vana Therapeutics, Northern Ireland
Day 1 - Ocular Drug Therapies - October 26th 10:35 - 11:05
Novel Engineered Supramolecular Enzyme Induced Self-Assembled Peptide (EISA) Gels for Sustained Release of a Corticosteroid, Targeting Anterior Segment Inflammation in the Eyes.
  • Shubham Baviskar - Postgraduate Research Fellow, Queen's University Belfast, Northern Ireland
Day 1 - Ocular Drug Therapies - October 26th 11:05 - 11:35
Break & Networking
Day 1 - Ocular Drug Therapies - October 26th 11:35 - 12:05
Biodegradable Silicon Nanoneedles for Ocular Drug Delivery
  • Yannis Paulus - Associate Professor, Ophthalmology and Visual Sciences, Kellogg Eye Centre, USA
Day 1 - Ocular Drug Therapies - October 26th 12:05 - 12:35
OTT166: A Small Molecule RGD-integrin Inhibitor for the Treatment of Diabetic Retinopathy
  • D. Scott Edwards - Chief Development Operating Officer, OcuTerra Therapeutics, Inc., USA
NextDay 2 - Oral Delivery of Macromolecules - October 27th
Filter
Streams
Choose Day